Although several reports have characterized the hematopoietic stem cell (HSC) transcriptome, the roles of HSC-specific genes in hematopoiesis remain elusive. To identify candidate regulators of HSC fate decisions, we compared the transcriptome of human umbilical cord blood and bone marrow CD34 
Introduction
Hematopoiesis is the process by which hematopoietic stem cells (HSCs) give rise to all hematopoietic lineages during the lifetime of an individual. To sustain lifelong hematopoiesis, HSCs must self-renew to maintain or expand the HSC pool [1] , and they must differentiate to form committed hematopoietic progenitor cells (HPCs) that progressively lose selfrenewal potential and become increasingly restricted in their lineage potential. A combination of extrinsic and intrinsic signals are thought to converge to regulate HSC differentiation versus self-renewal decisions, but the molecular mechanisms that regulate these processes are poorly understood [2] .
A multitude of cytokines have been cloned that affect HSCs and HPCs; however, to date none of these, alone or in combination, can induce the symmetrical, self-renewing HSC cell division in vitro that is required for HSC expansion. Recently, several novel regulators of HSC fate decisions have been identified. For instance, overexpression of Hoxb4 results in expansion of murine and human HSCs with an increased competitive repopulation potential [3] [4] [5] ; novel extrinsic regulators implicated in self-renewal of HSCs include Notch [6] , Wnt [7, 8] , and the morphogens, SHH (sonic hedgehog) [9] and BMP4 (bone morphogenetic protein 4) [9] . While the discovery of these novel regulators provides credence to the hypothesis that extrinsic and intrinsic signals can influence HSC fate, a more global gene and/or protein expression analysis of human HSC should provide additional insight into pathways that support HSC self-renewal.
Our current understanding of the expressed gene profile of HSCs comes primarily from murine HSCs that can be purified to near homogeneity [10] [11] [12] [13] [14] . The inability to purify human HSCs to similar degrees of homogeneity makes study of the transcriptome of human HSCs more difficult. Human HSCs and HPCs are CD34 positive, while cells that engraft in severe combined immunodeficiency (SCID) mice are enriched in the CD34 þ Lineage(Lin) À CD38
À fraction [15] . As fewer than 1/500 CD34 
CD38
À cells into HSC-enriched and HSC-depleted populations.
We hypothesized that comparison of the transcriptome of Rho lo and Rho hi cells from umbilical cord blood (UCB) and bone marrow (BM) should identify conserved genes and gene pathways that define the human HSC. Because of the inherent limitations of using gene expression data to infer biological gene function, we also assessed the hematopoietic role of these genes in a high-throughput in vivo functional genomics screen in the zebrafish. Using this strategy we have not only identified a series of genes that may represent novel regulators of human HSC fate decisions, but this work also represents, to our knowledge, the first example of a functional genetic screening strategy that is a critical step toward obtaining biologically relevant functional data from global gene-profiling studies. 
Results/Discussion

CD38
À cells [17] . Similar to our previous studies, the ML-IC frequency was greater than or equal to 10-fold higher in UCB Rho lo compared to Rho hi cells ( Figure S1 ).
Genes Differentially Expressed between Rho
lo and Rho hi Cells from Both UCB and BM
We hypothesized that comparing genes differentially expressed between Rho lo and Rho hi cells from ontogenically distinct sources would identify conserved genes and gene pathways that govern self-renewal and differentiation of human HSCs. The experimental design used is illustrated in Figure 1 . We defined differentially expressed probe sets as those with p , 0.05, using a paired Student's t-test. By taking into account the variability present in primary cell populations, this provides a more accurate analysis of differential gene expression compared with the commonly used fold change cutoff.
We identified 2,707 and 4,667 probe sets differentially expressed between Rho lo and Rho hi cells from UCB and BM, respectively (see Tables S1 and S2 ). The fidelity of our microarray results was confirmed using quantitative RT-PCR (Q-RT-PCR) (see Figure S2 ). We focused our further analysis on 277 unique transcripts, represented by 304 probe sets that were differentially expressed between Rho lo and Rho hi cells from both UCB and BM with a fold change greater than 1.5 in either UCB or BM (Table S3) . Among the conserved genes enriched in Rho lo cells, many have been implicated in early hematopoiesis, including CDKN1A, a cell cycle regulator required for maintenance of murine HSCs [18] , and ABCB1, the ABC-transporter family member responsible for the Rho lo phenotype [17] . Several transcription factors (TFs) known to play a role in early hematopoiesis or leukemogenesis were also identified, including HLF, involved in leukemogenic chromosomal translocations [19] and EVI1, a TF associated with myeloid leukemias [20] . Other TFs without a known role in hematopoiesis were also more highly expressed in Rho lo cells, including HMGA2, a high-mobility group gene, and the zinc finger TFs ZNF165, ZNF331, and KLF5. All Rho lo -enriched genes are listed in Table S3 . As demonstrated in previous HSC gene-profiling studies [12] [13] [14] , more than 40% of genes enriched in Rho lo cells lack a functional annotation, are hypothetical proteins, or are expressed sequence tags, and thus may represent currently uncharacterized regulators of HSC fate decisions ( Figure S3 ). Some genes with well-established roles in HSC self-renewal and early differentiation are not present in the Rho lo enriched gene list. However, most of these were differentially expressed in both datasets, but differences did not reach statistical significance. For instance, LMO2 [21] and GATA2 [22] , known to be involved in HSC development and selfrenewal, were expressed significantly higher in BM Rho lo than in Rho hi cells. Although similar trends were seen in UCB Rho lo cells, these differences were not statistically significant (Table S4 ). Conversely, HOXB4 [4] expression was significantly higher in UCB Rho lo than in Rho hi cells, but this difference was not statistically significant in BM. Although our stringent criteria for differential expression likely contribute to the omission of some genes that might be differentially expressed, another explanation might be that expression of these genes is maintained when cells differentiate from a Rho lo to a Rho hi stage. The latter is consistent with the fact that most known HSC-associated genes were expressed at much higher levels than the normalized average microarray expression level in Rho lo and in Rho hi cells from both UCB and BM (Table S4) .
Conserved genes enriched in the Rho hi cells included LEF1, an effector of Wnt signaling expressed in pre-B and T cells [23] , and NOTCH2, involved in hematopoietic differentiation cell-fate decision [24] . Several TFs known to play a role in hematopoietic cell differentiation were more highly expressed in Rho hi compared to Rho lo cells, including HELLS and MAFB [25, 26] . Additional TFs with no known role in hematopoietic development were also enriched in Rho hi cells, such as the zinc finger homeobox gene, ZFHX1B and the polycomb genes, EZH2 and SUZ12, the latter required for germ cell development [27] . Globin (Hb) gene family members were also more highly expressed in UCB and BM Rho hi than in Rho lo cells. Consistent with the ontogenic expression patterns of fetal versus adult Hb genes, Hbc genes were more highly expressed in perinatal UCB Rho hi cells, while Hbb genes were more highly expressed in adult BM Rho hi cells. Additional genes enriched in Rho hi cells are listed in Table  S3 .
Because of functional redundancy among gene families, we examined the data for common differentially expressed gene family members. The Id family of transcriptional repressors [28] was enriched in the Rho lo fraction, but was represented by different family members in UCB (ID4) and BM (ID1, ID2, and ID3). Similarly, various H1 and H2 histone genes were enriched in the Rho lo fraction in both datasets, but were represented by distinct family members.
We also evaluated whether common differentially expressed genes were concentrated on specific chromosomes. We found that genes were not only concentrated on certain chromosomes, but at specific g-band addresses. Of the genes enriched in Rho lo cells, 9% reside at 6p21, a region involved in recurrent chromosomal translocations in myeloid [29] and lymphoid [30] leukemias, and home to the PIM1 oncogene [31] . Six members of the H2B and one member of the H1 histone family, as well as CDKN1A, more highly expressed in Rho lo than Rho hi cells, reside at 6p21. The remaining Rho loenriched genes at 6p21 consist of six class II major histocompatibility complex (MHC) family members and a putative testis-specific zinc finger TF, ZNF165. H1 and H2 histone gene family members [11, 13] , class II MHC antigens [12, 13] , and CDKN1A [13] were also found among the genes identified in studies characterizing the transcriptome of murine HSC. The differential expression of such a large number of genes located at this chromosomal address suggests that, like CDKN1A, other genes located at 6p21 with as yet unknown hematopoietic function may play a role in HSC proliferation or differentiation.
We also compared the genes expressed more highly in Rho lo versus Rho hi cells with published gene expression data. 
. Functional Genomics Screen in Zebrafish
The hematopoietic function of differentially expressed candidate genes was determined by injecting MOs into one-to two-cell embryos from gata1:DsRed Tg zebrafish to disrupt gene expression. Injected embryos were scored at 30-48 hpf for the presence of DsRed þ blood cells by fluorescence microscopy. Subsequently, MO-targeted embryos with gross hematopoietic defects were analyzed for the expression of the early hematopoietic markers gata1 and scl by whole-mount in situ hybridization, and the late hematopoietic markers hbae1 and lcp1 by Q-RT-PCR. DOI: 10.1371/journal.pbio.0030254.g002
Comparison with the study by Ivanova et al. [12] (Table  S5 ), suggesting that HSC-specific genes are conserved across species.
In vivo functional genomics screen in zebrafish. Because gene profiling per se does not prove functional importance, we developed an in vivo functional genomics screen in zebrafish ( Figure 2 ). The zebrafish, Danio rerio, is an ideal organism for high-throughput genetic screens [32] as organogenesis is highly conserved from zebrafish to man [33] . There is abundant evidence that hematopoiesis in zebrafish occurs via a highly conserved genetic program. As in mammals, hematopoiesis in zebrafish occurs via specification of mesoderm to a hemangioblast stage that subsequently commits to either HSC or angioblasts [34] , and genes and signals involved in specification (BMP signaling) and commitment (vascular endothelial growth factor signaling; flk1, also known as kdr; lmo2; scl, also known as tal1; gata2; gata1) are conserved from fish to man [35] . This high degree of homology in the genetic control of zebrafish and human hematopoietic development makes genetic screens in zebrafish a powerful tool to elucidate the role of genes in hematopoiesis. Additionally, rapid reverse genetic screens can be accomplished using morpholino antisense oligonucleotides (MOs) to knock down gene expression in the developing zebrafish embryo [36] .
From the 277 unique transcripts that were differentially expressed between Rho lo and Rho hi cells of both UCB and BM (Table S3) , we eliminated genes with known function in hematopoiesis, MHC genes, histones, and genes that are known to play a role in glucose and protein metabolism and RNA and DNA synthesis, resulting in a final list of 158 genes. Of these, we identified a putative zebrafish ortholog for 86, and designed MOs against 61 (Table S6 ). The 61 MOs were injected in one-to two-cell zebrafish embryos and assayed for effects on blood development. Initial dosing studies identified 16/61 MOs that reduce blood cell production without confounding toxicities (Table 1 ). The 16 MOs induced a blood defect in more than 70% of embryos in two or more independent injections. Blood defects identified by gata1:DsRed transgenic (Tg) fluorescence microscopy were confirmed by Q-RT-PCR of the erythroid-specific hbae1 and myeloid-specific lcp1 transcripts in MO-targeted embryos compared to uninjected controls in three or more independent experiments of n ¼ 5 embryos per experiment. A greater than 2-fold reduction in both erythroid and myeloid gene expression levels were seen for five of seven MOs analyzed (see Table 1 ; Figures 3 and 4) . Thus, the addition of Q-RT-PCR to the screening process provides an independent confirmation and quantitation of the observed phenotypes, thereby limiting the false-positive rate, while maintaining the high-throughput nature of the screen. Additionally, the observed reduction of both erythroid and myeloid gene expression following knockdown of candidate genes is consistent with their presumed roles in HSC fate decisions prior to specification of the common myeloid progenitor. The validity of the Q-RT-PCR analysis was corroborated by analysis of hbae1 and lcp1 transcript levels in gata1 MOtargeted embryos, in which there was a virtually complete loss of hbae1 expression and an almost 2-fold increase in myeloidspecific lcp1 transcripts ( Figure 4 ) consistent with the published expression patterns for these genes following loss of gata1 expression [37] . Analysis of vascular development by injecting MOs into fli1:enhanced green fluorescent protein (EGFP) Tg embryos, which express EGFP in endothelial cells, demonstrated no major abnormalities in vascular morphogenesis or remodeling that precludes the circulation of the remaining blood cells, indicating that the hematopoietic defect is not secondary to a vascular phenotype ( Figure 4 ; Table S7 ). The greater than 20% frequency of blood defects seen in our screen compares very favorably with the 0.5%-1% frequency of hematopoietic phenotypes seen by ethylnitrosourea mutagenesis screens that mutate genes in a near random fashion [38] and the 4% of hematopoietic phenotypes seen in a morpholino-based functional screen of the zebrafish secretome [39] (S. C. Ekker, unpublished data). The high incidence of blood defects also demonstrates that the candidate genes identified by comparing the transcriptome of Rho lo and Rho hi cells represent genes with important roles in HSC biology. We were unable to identify a candidate ortholog in zebrafish for 72/158 of the differentially expressed human genes. This may be because currently only one quarter of the zebrafish genome is high-quality finished sequence. Hence, some genes with important roles in hematopoiesis may have been untested. However, from a sample of ten genes that lacked a zebrafish match, only one has a likely ortholog in the Fugu or Medaka sequencing projects, and thus incomplete genome coverage provides only a partial explanation. Alternative possibilities include a reduced level of primary sequence conservation between functional orthologs that would have been missed using our simple comparative genomics criteria, or that a number of genes are not conserved between fish and man, and thus might be less important for the conserved processes of hematopoietic selfrenewal and differentiation. Therefore, the relatively high incidence of blood defects in conserved genes may in part reflect ''evolutionary filtering'' in our screen. Consistent with this hypothesis, all zebrafish genes whose mutation resulted in a visible embryonic phenotype identified using a retroviral insertion strategy have a likely human ortholog [40] .
Although the frequency of blood defects is high, the screen is not as well suited for the identification of knockdown phenotypes that result in increased HSC proliferation and/or differentiation. We and others have successfully shown that dramatically increased hematopoietic development can be modeled in zebrafish, as is the case for knockdown of the BMP-antagonist chd (chordin) and the corresponding dino mutant [41, 42] ; however, more modest increases in hematopoietic cell production or skewing of lineage differentiation may be undetectable. Although these caveats may lead to underestimation of the true frequency of genes with a role in early hematopoietic development and differentiation, the screening procedure used has proven effective for extracting functional information from a global gene expression profiling dataset in a high-throughput manner.
Of note, viable knockout mice exist for 4/14 genes identified in our functional screen (Sparc, Irak3, Ccr7, and Prkch) [43] [44] [45] [46] . One could argue that if a viable knockout mouse exists, the gene of interest may not be important in hematopoiesis. However, lack of an overt hematopoietic phenotype does not preclude a role of a gene in HSC selfrenewal and differentiation, as this may only be detectable under conditions where the hematopoietic system is stressed or in transplantation experiments. For example, Hoxb4 À/À mice develop normally and present with only subtle differences in spleen and BM cellularity [47] . However, the proliferative response of HSC in vitro and in vivo is decreased, consistent with the observation that overexpression of Hoxb4 supports expansion of competitive repopulating units and SCID-repopulating cells [4, 5] .
Characterization of Sprouty Family Members in Zebrafish Hematopoiesis
To further verify the hematopoietic role of genes identified by gene array, we performed a more extensive evaluation of the zebrafish targeted with an MO against spry4 (spry4 morphant or spry4 MO ). Although human SPRY1 was differ- entially expressed, an MO against zebrafish spry4 was used, as it is expressed in the region of the lateral plate mesoderm, the first site of zebrafish hematopoiesis [48] , and it was the fulllength zebrafish Sprouty gene with the greatest protein homology to human SPRY1. Recently the partial sequence of a potential zebrafish spry1 ortholog was predicted by Ensembl's gene prediction software based on genomic sequence information. However, the single exon that was predicted does not contain an ATG start codon, or a conserved splice donor or acceptor site, and the putative zebrafish spry1 sequence only partially covers the human SPRY1 gene. Moreover, the genomic location of Ensembl's putative zebrafish spry1 is currently not known, and therefore it is not possible to use syntenic relationships to determine the most likely zebrafish ortholog for human SPRY1. At present, there is not sufficient sequence data available to design gain-or loss-of-function experiments for the putative zebrafish spry1, thus precluding an analysis of hematopoietic function in the zebrafish model. Therefore, spry4 is currently the best full-length, MO-targetable candidate ortholog for human SPRY1, and based on our results, at the very least zebrafish spry4 and SPRY1 share a conserved function in hematopoiesis.
To confirm the specificity of MO targeting in the spry4 MO , a second spry4 MO of independent sequence and a four-base mismatched spry4 MO were injected into zebrafish embryos. Injection of the independent spry4 MOs induced a hematopoietic phenotype in more than 65% of injected embryos, while the four-base mismatched MO did not induce any phenotypic changes (Figure 4 ). Q-RT-PCR for hbae1 and lcp1 transcripts also did not show changes in expression in fourbase mismatched MO embryos. Furthermore, the two independent spry4 MOs acted synergistically when coinjected (Figure 4 ). In addition to the blood phenotype, a slight facial outgrowth was seen at a low frequency. Also, a weak dorsalization phenotype was seen at 2-fold higher MO doses based on a decreased somite size.
To rule out the possibility that the hematopoietic defect observed in the spry4 MO was secondary to a vascular defect, we injected spry4 MO into fli1:EGFP Tg zebrafish. While the resulting embryos exhibited minor defects in cardinal vein remodeling and morphogenesis of intersegmental vessels in the posterior tail, there were no major defects in vascular development (Figure 4) . The integrity of the vascular network in spry4
MO fish was further demonstrated by the unimpeded circulation of the remaining DsRed þ blood cells in gata1:DsRed Tg spry4 MO (data not shown). Thisse et al. [35] have shown that overexpression of zebrafish spry4 mRNA leads to an expansion of the posterior intermediate cell mass (ICM) [48] . We overexpressed human SPRY1 in gata1:DsRed Tg zebrafish embryos, and observed a similar dose-dependent expansion of DsRed þ blood cells in the posterior ICM (Figure 4 ). Q-RT-PCR analysis of embryos overexpressing SPRY1 revealed a 1.7-and 1.4-fold increase hbae1 and lcp1 mRNA levels, respectively, confirming the observed expansion of blood cells in the ICM. Coinjection of human SPRY1 cDNA with spry4 MOs ameliorated the spry4 MO phenotype, yet another confirmation of the specificity of MO targeting (Figure 4) . The similar hematopoietic phenotypes observed following the overexpression of either human SPRY1 or zebrafish spry4 indicate that these genes encode proteins with a similar functional potential in blood development. In addition to the blood phenotype, the overexpression often caused a reduction and/or curve in the posterior tail ( Figure 4 ) not seen in the overexpression of zebrafish spry4 [48] .
Characterization of hematopoietic gene expression in the spry4
MO by whole-mount in situ hybridization revealed a reduction in scl expression at four somites (8/15), and virtually no scl (12/20) or gata1 (18/25) expression at 20 somites ( Figure 5 ), consistent with a defect in mesodermal commitment to HSCs and/or HSC proliferation and differentiation. The few hematopoietic cells that are present in the morphant are hemoglobinized based on o-dianisidine staining (data not shown). To determine whether the hematopoietic defects observed in spry4 MO were the result of a defect in mesoderm specification during development, we performed whole-mount in situ hybridization for the vasculature-specific flk1 and musclespecific myod transcripts. At 10 h postfertilization (hpf) there was a slight defect in myod expression (5/10), while myod expression at 26 hpf was comparable to wild type (21/21) ( Figure 5 ). This suggests that there were no major defects in mesodermal commitment in the spry4 morphants. Considering the nearly absent expression of the early hemangioblast and HSC cell marker scl, these results may suggest that the defect induced in the spry4 MO occurs prior to HSC specification. However, the normal expression pattern of other mesodermal genes, such as flk1 and myod at 26 hpf in the spry4 MO ( Figure 5 ), indicate that the hematopoietic phenotype is not merely a consequence of defective specification of mesoderm. Finally, the hematopoietic gene cmyb, a presumed marker of definitive HSC in zebrafish [49] , was absent at 38 hpf (10/12) (data not shown), suggesting that the spry4 MO embryos are devoid of definitive HSC.
In vertebrates, Sprouty family members act as antagonists for fibroblast growth factor (FGF), vascular endothelial growth factor, and epidermal growth factor signaling, and they may be involved in feedback regulation, as Sprouty gene expression is induced by activation of these signaling pathways [50] . Sprouty genes antagonize receptor tyrosine kinase signaling at the level of the Ras/Raf/mitogen-activated protein kinase pathway; however, they also can serve as positive regulators of these pathways in some cell types [50] . Therefore, our current hypothesis is that SPRY1 may affect HSC by modulating FGF-mediated, perhaps in combination with other receptor tyrosine kinase-mediated, signaling. In fact, three of the 14 genes that induce a hematopoietic defect in the zebrafish screen, SPRY1, MAFB and SPARC, are all involved in FGF signaling [50] [51] [52] , thus suggesting a role for FGF in hematopoiesis. Studies are ongoing to confirm a role of SPRY1 in mammalian hematopoiesis, by testing the effect of overexpression of SPRY1 on the repopulating ability of human and murine HSCs. Similar definitive studies in zebrafish and subsequent confirmation in mammalian HSC models are underway for genes that were functionally validated in our zebrafish screen. We believe that the sequential genetic screen in zebrafish followed by confirmation in mammalian models as described here will establish a hematopoietic function for genes identified by gene array analysis in a high-throughput and efficient manner.
Materials and Methods
Isolation of Rho lo and Rho hi cell populations from UCB and BM. Human UCB from full-term delivered infants and BM from healthy donors were obtained after informed consent in accordance with guidelines approved by the University of Minnesota Committee on the Use of Human Subjects in Research. Each biologically distinct replicate was comprised of one to four donors for UCB and individual donors for BM samples. CD34
hi fractions were selected by sequential FicollHypaque separation, MACS column depletion, and fluorescenceactivated cell sorting as previously described [17] . Postsort analysis MO embryos compared to uninjected controls. (B) The more mature hematopoietic marker gata1 was also reduced in spry4 MO compared to uninjected zebrafish embryos at 20 somites. (C and D) In contrast to hematopoietic genes, the mesodermal-specific flk1 (vasculature) transcripts were expressed at similar levels to uninjected controls at 26 hpf, and myod (muscle) had a slight defect (arrowhead) at 10 hpf, while expression was similar to controls at 26 hpf. All images are representative of greater than or equal to two experiments of n ! 8 embryos. DOI: 10.1371/journal.pbio.0030254.g005 demonstrated that sorted populations contained fewer than 1%-2% contaminating cells from the opposing population (see Figure 1) .
Determination of ML-IC frequencies. ML-IC frequencies for UCB samples (n ¼ 3) were determined as previously described [17] . An ML-IC was defined as a single cell that gave rise to at least one LTC-IC and one NK-IC. Results are presented as ML-IC frequency 6 standard deviation of the mean.
Processing of RNA samples and oligonucleotide microarray analysis. Total cellular RNA was isolated from UCB (n ¼ 5) and BM (n ¼ 4) Rho lo and Rho hi cells using the PicoPure RNA Isolation Kit (Arcturus, Mountain View, California, United States) per the manufacturer's instructions. Seven to 10,000 Rho lo and Rho hi cells were sorted directly into 100 ll extraction buffer (XB) provided with the PicoPure RNA Isolation Kit prior to RNA isolation. Labeled cRNA was generated by one round of IVT-based, linear amplification using the RiboAmp OA RNA Amplification Kit (Arcturus) followed by labeling with the Enzo Bioarray HighYield RNA Transcript Labeling Kit (Enzo Life Sciences, Farmingdale, New York, United States) according to manufacturer's instructions. Samples were hybridized to Affymetrix HG-U133 A and B chips (Affymetrix Inc., Santa Clara, California, United States) were washed, and scanned at the University of Minnesota Affymetrix Microarray Core Facility as described in the Affymetrix GeneChip Expression Analysis Technical Manual.
Oligonucleotide microarray data analysis. Affymetrix HG-U133 GeneChips were processed using GeneData Refiner software (GeneData, San Francisco, California, United States) to assess overall quality. Feature intensities for each chip were condensed into a single intensity value per gene using the Affymetrix Statistical Algorithm (MAS 5.0) with s ¼ 0.015, a1 ¼ 0.04, a2 ¼ 0.06, and a scaling factor of 500. Expression data was analyzed using GeneData' 
gov/david).
Microarray Q-RT-PCR confirmation. Labeled cRNA was reverse transcribed to generate cDNA using SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, California, United States) according to manufacturer's instructions. Q-RT-PCR was performed using the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, California, United States). Briefly, 3 ng of cDNA was amplified by 40 cycles of a two-step PCR reaction (95 8C for 15 s denaturation and 60 8C for 1 min. annealing/elongation) containing 100 nM gene-specific primers (Table S8 ) and the SYBR Green PCR Master Mix (Applied Biosystems). Gene expression was normalized using human ACTB (also b-actin) expression levels. Results are presented as percent expression relative to uninjected clutchmate control embryos 6 standard deviation of the mean.
High-throughput loss-of-function genetic screen in zebrafish. The likely zebrafish orthologs of differentially expressed human genes were identified using Ensembl's gene homology prediction program (http:// www.ensembl.org, build Zv3) in combination with comparison of the human protein sequence to the Institute for Genomic Research zebrafish EST database (http://www.tigr.org, release [13] [14] [15] . The criteria for a likely ortholog was ! 40% amino acid identity over the entire length of the protein or ! 50% if the fish protein sequence was only partial. MO (Gene Tools, Philomath, Oregon, United States) sequences were designed complimentary to the region of translational initiation of the zebrafish orthologs in order to inhibit protein translation (Table S6 ) and injected into one-to two-cell zebrafish embryos as previously described [36] . MOs were injected at 1.5, 3, 4.5, and 6 ng into 50-70 embryos derived from mating Tg zebrafish containing a fluorescent DsRed reporter cassette driven by the gata1 promoter (gata1:DsRed Tg) or a fluorescent EGFP reporter cassette driven by the fli1 promoter (fli1:EGFP Tg). MO-targeted (morphant) zebrafish were evaluated for defects in hematopoietic and vascular development compared to uninjected controls from the same embryo clutch at 30 and 48 hpf, using fluorescence microscopy for visualization of DsRed þ blood cells and EGFP þ vasculature. Whole zebrafish Q-RT-PCR confirmation. Total RNA was isolated from five MO-injected zebrafish embryos at 48 hpf with hematopoietic defects, determined based on gata1:DsRed þ hematopoietic cell production, or five uninjected clutchmate controls using the RNeasy Mini Kit (Qiagen, Valencia, California, United States) according to the manufacturer's instructions. Total RNA was incubated with DNaseI (Invitrogen) to digest contaminating genomic DNA, and reverse transcribed to generate cDNA using SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol. Q-RT-PCR was performed using the ABI Prism 7000 Sequence Detection System (Applied Biosystems). Briefly, 1/20 of the total cDNA from five zebrafish embryos was amplified by 40 cycles of a two-step PCR reaction (95 8C for 15 s denaturation and 60 8C for 1 min. annealing/elongation) containing 100 nM gene-specific primers (Table S8 ) and the SYBR Green PCR Master Mix (Applied Biosystems). Gene expression was normalized using a zebrafish gapd expression level. Results are presented as percentage expression relative to uninjected clutchmate control embryos 6 standard deviation of the mean.
Whole-mount in situ hybridization. The scl, myod, flk1, gata1, and cmyb riboprobes were generated and whole-mount in situ hybridization of zebrafish embryos was conducted as previously described [41] .
Overexpression of human and zebrafish Sprouty gene family members. The XhoI and KpnI fragment of the SPRY1 open reading frame (ORF) (Open Biosystems, Huntsville, Alabama, United States) was cloned into pENTR1A (Invitrogen) and subsequently transferred into a modified pFRM2.1 zebrafish expression vector using the Gateway cloning system (Invitrogen) to create the pFRM2.1-SPRY1 vector. pFRM2.1-SPRY1 was coinjected with pFRM2.1-EGFP at a 5:1 ratio into the yolk/cell interface of one-cell gata1:DsRed Tg zebrafish embryos as described for MO injections. Defects in hematopoietic development of EGFP þ embryos were analyzed by comparison to embryos from the same clutch injected with pFRM2.1-EGFP alone, using fluorescence microscopy to visualize DsRed þ blood cells.
Supporting Information Figure S1 . The microarray data in this manuscript have been deposited in the GEO database (http://www.ncbi.nlm.nih.gov/geo/), and have been assigned the accession number GSE2666.
